The first diabetic dog in the study was enrolled in December 2025: a 12-year-old mixed-breed dog with a long history of diabetes, who has been under specialist veterinary care since August 2025.

With close follow-up and strong veterinary expertise, adjustments were made to the dog’s diabetes management during the study period, contributing to improved glucose control and overall well-being.

Lifecare’s veterinary study is also designed to generate practical learning for product development and future human clinical programs.

Real-life improvement in diabetes management

Following study enrolment, the dog has been closely monitored by veterinarians at the Norwegian University of Life Sciences (NMBU). During the initial phase, the veterinarians were able to optimise diabetes management based on enhanced access to continuous glucose insight and close clinical follow-up. This resulted in observable improvements in glucose regulation and overall well-being.

The improvements are attributed to a clinician-led approach, combined with frequent monitoring and a better understanding of glucose patterns over time, supporting more informed treatment adjustments.

“Based on feedback from the veterinarians involved in the study, the participating dog shows clear improvements in overall well-being and diabetes management compared to earlier in the disease course,” says Joacim Holter, CEO of Lifecare. “This highlights the practical value of close monitoring and continuous glucose insight in veterinary diabetes care.”

Veterinary studies as a learning platform for development

Initial data from LFC-SEN-002 demonstrate the practical relevance of continuous glucose insight in veterinary diabetes care.

Insights from long-term in-vivo operation, real-world glucose dynamics, and system behaviour in a biological environment are informing further optimisation of the implant and supporting preparation for future human clinical programs.

“Veterinary medicine allows us to observe how continuous glucose insight supports real clinical care within a clinician-led decision-making framework,” Holter adds. “These learnings are highly valuable for our product development and help de-risk future human programs, while we remain disciplined in the use of investigational devices.”

Strengthening the veterinary pathway and human roadmap

Early experience from LFC-SEN-002 strengthens Lifecare’s confidence in:

• the relevance of continuous glucose monitoring in veterinary diabetes care,
• the company’s planned veterinary market pathway, and
• the role of veterinary studies as an important step in Lifecare’s broader development and regulatory strategy.

The study continues to generate data supporting both veterinary market preparation and progress toward first-in-human studies and CE marking.

About LFC-SEN-002

LFC-SEN-002 is an ongoing longevity and performance study evaluating Lifecare’s implantable CGM technology in dogs. The study focuses on biocompatibility, system stability, and in-vivo signal behaviour, and supports both veterinary product development and future human clinical programs. The study is conducted under veterinary supervision in cooperation with the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences at the Norwegian University of Life Sciences. Data generated in the study provide direct input to Lifecare’s ongoing development and execution program.